Editorial Commentary
Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
Abstract
The first-line treatment scenario of advanced non-small cell lung cancer (NSCLC) has been substantially revolutionized in the very last years, since immunotherapy has become a cornerstone.
